The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Exclusion Criteria

• •Planned coronary (PCI or CABG) or other arterial revascularization.
• •New York Heart Association Class IV congestive heart failure or left ventricular ejection fraction \< 25% by cardiac imaging.
• •Chronic renal insufficiency with creatinine clearance of \<30 ml/min/1.73m\^2 by MDRD formula or with end state renal disease on dialysis.
• •History of hemorrhagic stroke.
• •Prior exposure to bococizumab or other investigational PCSK9 inhibitor.